CVS Health Corporation CVS
89.13
4.08
4.80%
as of 25 Sep
- Market cap
- $108.5B
- P/E
- 23.3×
Follow CVS
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
CVS Health Corporation (CVS) EBITDA
CVS Health Corporation's EBITDA for fiscal 2025 was $15.0B, up 14.3% from $13.1B in fiscal 2024. Over the twelve months to 30 June 2026 it was $18.5B. Over the past ten years it has ranged from $11.6B (fiscal 2015) to $18.4B (fiscal 2020); the current reading is higher than 64% of that period. CVS Health Corporation ranks 2nd of 12 Healthcare Plans companies by EBITDA.
EBITDA, annual
Annual
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $15.0B | 14.32% |
| FY2024 | $13.1B | (27.59%) |
| FY2023 | $18.1B | 48.70% |
| FY2022 | $12.2B | (33.19%) |
| FY2021 | $18.2B | (0.68%) |
| FY2020 | $18.4B | 12.19% |
| FY2019 | $16.4B | 26.92% |
| FY2018 | $12.9B | 5.66% |
| FY2017 | $12.2B | (5.16%) |
| FY2016 | $12.9B | 11.19% |
Quarterly
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $5.8B | 0.59% |
| Mar 2026 | $5.8B | 77.82% |
| Dec 2025 | $3.3B | (10.76%) |
| Sep 2025 | $3.7B | 2.82% |
| 42 more quarters | Free account |
Against its own ten years
Low $11.6B
High $18.4B
Ten-year median
$13.1B
Current reading's percentile
64
EBITDA against peers
| Company | EBITDA |
|---|---|
| UNH UnitedHealth Group Incorporated compare | $26.0B |
| CVS CVS Health Corporation | $18.5B |
| CI Cigna Group compare | $12.7B |
| ELV Elevance Health, Inc. compare | $8.8B |
| HUM Humana Inc. compare | $3.5B |
| OSCR Oscar Health, Inc. compare | $632.0M |
| MOH Molina Healthcare, Inc compare | $371.0M |
| CLOV Clover Health Investments, Corp. compare | −$18.2M |
| CNC Centene Corporation compare | −$4.4B |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on CVS
- Revenue
- Net income
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement